Aggiudicatario

Abacus Medicine AS

Kopenhagen V · DNK

Segui questa schedaCon Adjudera Pro ricevi un avviso prima che un contratto qui scada.

Aggiudicazioni

Importo totale aggiudicato

—

0 / 15 con importo

Stazioni appaltanti

Settori

Gruppo: Abacus Medicine AS

Reg. Umsatzsteuer Ident Nr: DE299584466

Contratti di questo aggiudicatario in scadenza

31 dic 2026
dichiarata
Cetuximab 100 mg in 20 ml Lsg. Infusionslösung St a 20 ml
PBMG eGAbacus Medicine AS
—
30 giu 2027
dichiarata
Cabotegravir 600 mg in 3 ml Lsg. Depot-Injektionssuspension St a 3 ml
PBMG eGAbacus Medicine AS
—
30 giu 2027
dichiarata
Degarelix 80 mg in 4 ml Fertiglsg. Pulver u. Lösungsmittel zur Herstellung einer Injektionslsg. Depot St
PBMG eGAbacus Medicine AS
—
30 giu 2027
dichiarata
Galsulfase 5,0 mg / 5 ml Infusionslösungskonzentrat St
PBMG eGAbacus Medicine AS
—
30 giu 2027
dichiarata
Dornase alfa 2,5 mg in 2.5 ml Lsg. Lösung für einen Vernebler St
PBMG eGAbacus Medicine AS
—
30 giu 2027
dichiarata
Glecaprevir 100 mg, Pibrentasvir 40 mg Filmtabletten St
PBMG eGAbacus Medicine AS
—
30 giu 2027
dichiarata
Granisetron 3,1 mg/d in 52 qcm Pflaster Pflaster transdermal konstante Freisetzung St
PBMG eGAbacus Medicine AS
—
30 giu 2027
dichiarata
Palivizumab 100 mg Injektionslösung 1 ml Lsg. St a 1.0 ml
PBMG eGAbacus Medicine AS
—
30 giu 2027
dichiarata
Palivizumab 50 mg Injektionslösung 0.5 ml Lsg. St a 0.5 ml
PBMG eGAbacus Medicine AS
—
30 giu 2027
dichiarata
Poly(styrol-co-divinylbenzol)sulfonsäure (92:8), Natriumsalz 14,99 g Pulver St a 400-500 g
PBMG eGAbacus Medicine AS
—
30 giu 2027
dichiarata
Raltegravir 400 mg Filmtabletten St
PBMG eGAbacus Medicine AS
—
30 giu 2027
dichiarata
Sofosbuvir 400 mg, Velpatasvir 100 mg Filmtabletten St
PBMG eGAbacus Medicine AS
—
30 giu 2027
dichiarata
Tolvaptan 45 mg, Tolvaptan 15 mg Tabletten (Indikation wie Jinarc) St
PBMG eGAbacus Medicine AS
—
30 giu 2028
dichiarata
Raltegravir 600 mg Filmtabletten St
PBMG eGAbacus Medicine AS
—
30 giu 2028
dichiarata
Clostridium botulinum (Onabotulinum) Toxin Typ A 100 E. Pulver zur Herstellung einer Injektionslösung (medizinische Indikation) St
PBMG eGAbacus Medicine AS
—

Tutti i contratti in scadenza →

Aggiudicazioni

Aggiudicazione	Stazione appaltante	Aggiudicatario	Importo dell’appalto	Pubblicato
Clostridium botulinum (Onabotulinum) Toxin Typ A 100 E. Pulver zur Herstellung einer Injektionslösung (medizinische Indikation) St	PBMG eG	Abacus Medicine AS	—	12 mag 2026
Cetuximab 100 mg in 20 ml Lsg. Infusionslösung St a 20 ml	PBMG eG	Abacus Medicine AS	—	27 feb 2026
Raltegravir 600 mg Filmtabletten St	PBMG eG	Abacus Medicine AS	—	27 feb 2026
Tolvaptan 45 mg, Tolvaptan 15 mg Tabletten (Indikation wie Jinarc) St	PBMG eG	Abacus Medicine AS	—	27 feb 2026
Sofosbuvir 400 mg, Velpatasvir 100 mg Filmtabletten St	PBMG eG	Abacus Medicine AS	—	27 feb 2026
Raltegravir 400 mg Filmtabletten St	PBMG eG	Abacus Medicine AS	—	27 feb 2026
Poly(styrol-co-divinylbenzol)sulfonsäure (92:8), Natriumsalz 14,99 g Pulver St a 400-500 g	PBMG eG	Abacus Medicine AS	—	27 feb 2026
Palivizumab 50 mg Injektionslösung 0.5 ml Lsg. St a 0.5 ml	PBMG eG	Abacus Medicine AS	—	27 feb 2026
Palivizumab 100 mg Injektionslösung 1 ml Lsg. St a 1.0 ml	PBMG eG	Abacus Medicine AS	—	27 feb 2026
Granisetron 3,1 mg/d in 52 qcm Pflaster Pflaster transdermal konstante Freisetzung St	PBMG eG	Abacus Medicine AS	—	27 feb 2026
Glecaprevir 100 mg, Pibrentasvir 40 mg Filmtabletten St	PBMG eG	Abacus Medicine AS	—	27 feb 2026
Dornase alfa 2,5 mg in 2.5 ml Lsg. Lösung für einen Vernebler St	PBMG eG	Abacus Medicine AS	—	27 feb 2026
Galsulfase 5,0 mg / 5 ml Infusionslösungskonzentrat St	PBMG eG	Abacus Medicine AS	—	27 feb 2026
Degarelix 80 mg in 4 ml Fertiglsg. Pulver u. Lösungsmittel zur Herstellung einer Injektionslsg. Depot St	PBMG eG	Abacus Medicine AS	—	27 feb 2026
Cabotegravir 600 mg in 3 ml Lsg. Depot-Injektionssuspension St a 3 ml	PBMG eG	Abacus Medicine AS	—	27 feb 2026